Fungal Alterations in Inflammatory Bowel Diseases Fungal Alterations in Inflammatory Bowel Diseases

This review explores the role of gut fungi in patients with Crohn's disease and ulcerative colitis. Might modulation of the fungal microbiota present a therapeutic opportunity for IBD?Alimentary Pharmacology &Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Related Links:

Conclusion: Two-thirds of the patients demonstrated stable clinical benefit from maintenance IFX. The results show steroid-sparing efficacy as well as improved quality of life and reduced need for surgery. PMID: 32052663 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Recent evidence points to a plausible role of diet and the microbiome in the pathogenesis of both Crohn ’s disease (CD) and Ulcerative Colitis (UC). Dietary therapies based on exclusion of table foods and replacement with nutritional formulas and/or a combination of nutritional formulas and specific table foods may induce remission in CD. In UC, specific dietary components have also been associated with flare of disease. While evidence of varying quality has identified potential harmful or beneficial dietary components, physicians and patients at the present time do not have guidance as to which foods are safe, may b...
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
In recent years, despite the persistence of heterogeneous definitions, mucosal healing has become a relevant goal in the treatment of patients with inflammatory bowel disease (IBD) [1]. In addition, in ulcerative colitis (UC), histological healing has demonstrated a potential prognostic value, overcoming the macroscopic endoscopic exclusive evaluation [2], and allowing that histological improvement could be suggested as a relevant end-point for clinical trials by European and American regulatory agencies.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Source Type: research
CONCLUSION: Of the biological agents, vedolizumab and infliximab were the most effective, suggesting that biological agents are still a better choice. Nevertheless, tofacitinib and FMT may be promising alternatives with high efficacies. However, more safety and maintenance studies need to be conducted in future for the acquisition of more accurate results.Abbreviations: FMT: Fecal microbiota transplantation; UC: Ulcerative colitis; RCTs: Randomized controlled trials; IBD: Inflammatory bowel disease; CD: Crohn's disease; IBS: Irritable bowel syndrome; CDI: Clostridium difficile infections; ITT: Intention-to-treat; RR: Relat...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
CONCLUSIONS: Biological drugs could lead to a positive immunomodulation towards HPV infection. In IBD patients an alteration of the vaginal and intestinal microbiota seems to be coexisting. PMID: 32016957 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Selection, via host immunity, is often required to foster beneficial microbial symbionts and suppress deleterious pathogens. In animals, the host immune system is at the center of this relationship. Failed host immune system-microbial interactions can result in a persistent inflammatory response in which the immune system indiscriminately attacks resident microbes, and at times the host cells themselves, leading to diseases such as Ulcerative Colitis, Crohn’s Disease, and Psoriasis. Host genetic variation has been linked to both microbiome diversity and to severity of such inflammatory disease states in humans. Howev...
Source: G3: Genes Genomes Genetics - Category: Genetics & Stem Cells Authors: Tags: Genetics of Immunity Source Type: research
Conditions:   Ulcerative Colitis (UC);   Crohn's Disease Interventions:   Drug: Risankizumab;   Drug: Cytochrome P450 (CYP) Substrates Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION:  This study showed a need of information concerning symptoms, nutrition and therapy that should be considered during patient education. Since time in physician patient dialogue is short it may be helpful to further evaluate websites independently in order to give recommendations of websites offering reliable information. PMID: 32018314 [PubMed - as supplied by publisher]
Source: Zeitschrift fur Gastroenterologie - Category: Gastroenterology Authors: Tags: Z Gastroenterol Source Type: research
Conclusion Infliximab and adalimumab showed similar drug survival as first- and second-line anti-tumour necrosis factor treatments. Therapeutic drug monitoring was associated with higher drug survival for both first- and second-line anti-tumour necrosis factor treatments.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
AbstractInflammatory bowel diseases (IBD), including Crohn ’s disease, ulcerative colitis, and pouchitis, are chronic, relapsing intestinal inflammatory disorders mediated by dysregulated immune responses to resident microbiota. Current standard therapies that block immune activation with oral immunosuppressives or biologic agents are generally effective, but each therapy induces a sustained remission in only a minority of patients. Furthermore, these approaches can have severe adverse events. Recent compelling evidence of a role of unbalanced microbiota (dysbiosis) driving immune dysfunction and inflammation in IBD ...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
More News: Crohn's Disease | Drugs & Pharmacology | Gastroenterology | Health | Inflammatory Bowel Disease | Ulcerative Colitis